Coagulation Modifier Drugs (final)

Principles of Hemostasis and the Coagulation Cascade

  • Hemostasis refers to any physiological process that stops bleeding.

  • Coagulation is a specific form of hemostasis that results from the physiological clotting of blood.

    • It involves a complex relationship between substances that promote clot formation and those that either inhibit coagulation or dissolve a formed clot.

  • Thrombus is the technical term for a blood clot.

  • Embolus is a thrombus that has detached and is moving through blood vessels.

  • The Coagulation Cascade

    • Each activated factor in the cascade serves as a catalyst to amplify the subsequent reaction.

    • The end result of this process is the production of fibrin, which is a clot-forming substance.

    • The cascade is divided into the intrinsic pathway and the extrinsic pathway.

    • Extrinsic Pathway: Triggered by tissue trauma. It involves Factor VIIVII becoming Activated VIIaVIIa. Along with Tissue Factor (Factor IIIIII) and Calcium (Ca++Ca^{++}), it leads to the activation of Factor XX.

    • Intrinsic Pathway: Triggered by blood trauma or contact with collagen. It involves a sequence: Factor XII→XIIa→XI→XIa→IX→IXaXII \rightarrow XIIa \rightarrow XI \rightarrow XIa \rightarrow IX \rightarrow IXa. Factor IXaIXa works with Factor VIIIVIII, platelets, and Ca++Ca^{++} to activate Factor XX.

    • Common Pathway: Activated Factor XX (XaXa) works with Factor VV, platelets, and Ca++Ca^{++} to convert Prothrombin (Factor IIII) into Thrombin (Factor IIaIIa). Thrombin then converts Fibrinogen (Factor II) into soluble fibrin, which is stabilized into insoluble fibrin by Activated Factor XIIIXIII (XIIIaXIIIa).

    • Vitamin K-Dependent Clotting Factors: Factors IIII, VIIVII, IXIX, and XX require Vitamin K for synthesis in the liver.

Mechanisms and Biological Systems of Fibrinolysis

  • Fibrinolytic System: This system initiates the breakdown of clots and serves as a balance to the clotting process to prevent excessive formation.

  • Fibrinolysis: The specific mechanism by which formed thrombi are lysed (broken down) to prevent the blockage of blood vessels.

    • Plasminogen: A circulating protein that binds to the fibrin within a clot.

    • Plasmin: When plasminogen binds to fibrin, it is converted into plasmin. Plasmin is an enzymatic protein that breaks down the fibrin thrombus into fibrin degradation products.

    • This enzymatic action keeps the thrombus localized, preventing it from becoming a dangerous embolus.

Classification of Coagulation Modifier Drugs

  • Anticoagulants: Also known as antithrombotic drugs. They inhibit the action or formation of clotting factors to prevent clot formation. They have no direct effect on clots that have already formed.

  • Antiplatelet Drugs: These inhibit platelet aggregation to prevent the formation of platelet plugs.

  • Hemorheological Drugs: These alter platelet function without completely preventing the platelets from working.

  • Thrombolytic Drugs: These drugs lyse (break down) existing clots that have already formed.

  • Antifibrinolytic (Hemostatic) Drugs: These promote blood coagulation.

Pharmacology and Administration of Heparins

  • Mechanism of Action: Heparins inhibit clotting factors IIaIIa (Thrombin), XaXa, and IXIX. Factors XIXI and XIIXII are also inactivated, though they play a less significant role.

  • Unfractionated Heparin ("Heparin"):

    • A natural anticoagulant obtained from the lungs or intestinal mucosa of pigs.

    • Available as Heparin Sodium in concentrations ranging from 1010 to 10,000 units/mL10,000\,units/mL.

    • Requires frequent laboratory monitoring using activated Partial Thromboplastin Time (aPTT).

    • Monitoring occurs every 66 hours until a therapeutic effect is established.

    • For DVT prophylaxis, a standard dose is 5000 units5000\,units subcutaneously 22 to 33 times daily. In this prophylactic setting, aPTT monitoring is generally not required.

  • Low-Molecular-Weight Heparins (LMWHs):

    • Synthetic drugs with a smaller molecular structure compared to unfractionated heparin.

    • Provide a more predictable anticoagulant response.

    • Frequent laboratory monitoring of aPTT is not required.

    • Examples:

      • enoxaparin (Lovenox)

      • dalteparin (Fragmin)

      • nadroparin calcium (Fraxiparine)

      • tinzaparin sodium (Innohep)

  • Adverse Effects of Heparin:

    • Bleeding.

    • Heparin-Induced Thrombocytopenia (HIT):

      • Type I HIT: Characterized by a gradual reduction in platelets. Heparin therapy can usually be continued.

      • Type II HIT: Characterized by an acute fall in platelet count (more than 50%50\% reduction from baseline). Heparin therapy must be discontinued immediately. Incidence ranges from 5%5\% to 15%15\% of patients and is more common with unfractionated heparin than LMWH. Thrombosis in the presence of HIT can be fatal.

      • Treatment for HIT: Thrombin inhibitors such as bivalirudin and argatroban.

  • Toxicity Management:

    • Symptoms of toxicity include hematuria, melena, petechiae, ecchymoses, and bleeding from the gums or mucous membranes.

    • The drug must be stopped immediately.

    • Antidote: Protamine sulphate IV.

      • 1 mg1\,mg of protamine sulphate can reverse the effects of 100 units100\,units of heparin.

      • 1 mg1\,mg of protamine sulphate is given for each milligram of LMWH administered.

Warfarin (Coumadin) Therapy and Monitoring

  • Mechanism of Action: Warfarin is the most commonly prescribed oral anticoagulant. It inhibits the synthesis of Vitamin K by bacteria in the gastrointestinal tract. This, in turn, inhibits the production of Vitamin K-dependent clotting factors (IIII, VIIVII, IXIX, and XX) in the liver.

  • Monitoring Parameters:

    • Prothrombin Time (PT)

    • International Normalized Ratio (INR)

    • A normal INR for a person not on warfarin is 0.80.8 to 1.21.2.

    • A therapeutic INR for a person on warfarin is typically between 22 and 3.53.5.

  • Adverse Effects: Bleeding, lethargy, muscle pain, skin necrosis, and "purple toes" syndrome.

  • Toxicity Management:

    • Discontinue warfarin.

    • Antidote: Vitamin K1 (phytonadione). High doses (10 mg10\,mg) given intravenously can reverse anticoagulation within 6 hours6\,hours.

    • Giving Vitamin K can cause warfarin resistance for up to 77 days afterward.

    • For severe bleeding, transfusions of human plasma or clotting factor concentrates may be necessary.

  • Key Considerations: Maintenance doses are determined by INR. Clinicians must consider the patient's age and variations in specific genes such as CYP2C9CYP2C9 and VKORC1VKORC1.

Direct-Acting Anticoagulants

  • Antithrombin Medications: These inhibit Thrombin (Factor IIaIIa).

    • Natural: Human antithrombin III (Thrombate).

    • Synthetic: Lepirudin (Refludan), argatroban (Argatroban), bivalirudin (Angiomax), and dabigatran (Pradaxa).

  • Direct Acting Xa Inhibitors: These target Factor XaXa specifically.

    • Examples: Fondaparinux (Arixtra), rivaroxaban (Xarelto), and apixaban (Eliquis).

  • Direct Thrombin Inhibitors:

    • Example: Dabigatran.

Indications and Contraindications for Anticoagulants

  • Indications: Anticoagulants are used prophylactically to prevent clot formation and emboli in high-risk settings, including:

    • Myocardial infarction,

    • Unstable angina,

    • b

    • Mechanical heart valves,

    • Major orthopedic surgery,

    • Prolonged immobility.

  • Contraindications:

    • Known drug allergy.

    • Acute bleeding processes or a high risk of acute bleeding.

    • Pregnancy: Warfarin is strongly contraindicated.

    • Epidural Catheters: LMWHs are contraindicated in patients with an indwelling epidural catheter due to the risk of an epidural hematoma.

  • Interactions: Anticoagulant interactions are profound and complex. They often involve enzyme inhibition of metabolism, displacement from protein-binding sites, decreased Vitamin K synthesis/absorption in the large intestine, and alterations in platelet activity.

Antiplatelet and Thrombolytic Drugs

  • Antiplatelet Drugs:

    • Mechanism: Prevent platelet adhesion and aggregation.

    • Examples: Aspirin, clopidogrel bisulfate (Plavix), prasugrel (Effient), treprostinil (Remodulin), abciximab (ReoPro), eptifibatide (Integrilin), tirofiban (Aggrastat), anagrelide hydrochloride (Agrylin), and dipyridamole (Aggrenox, Persantine).

    • Cyclooxygenase Pathway: Platelets use cyclooxygenase to produce Thromboxane A2 (TXA2TXA_2), which causes vasoconstriction and platelet aggregation. Aspirin inhibits this pathway. Blood vessel walls use the same pathway to produce prostacyclin, which causes dilation and inhibits aggregation.

  • Thrombolytic Drugs:

    • Mechanism: Activate the fibrinolytic system by converting plasminogen to plasmin, which then lyses (breaks down) the thrombus quickly. This mimics the body's natural clot destruction process.

    • Current Examples: Alteplase (Activase), tenecteplase (TNKase).

    • Older Examples: Streptokinase, urokinase.

    • Indications: Acute myocardial infarction, arterial thrombolysis, deep vein thrombosis (DVT), occlusion of shunts or catheters, pulmonary embolism, and acute ischemic stroke.

    • Adverse Effects: Internal, intracranial, or superficial bleeding; nausea, vomiting, hypotension, hypersensitivity, anaphylactoid reactions, and cardiac dysrhythmias.

Antifibrinolytic Drugs

  • Mechanism of Action: These drugs prevent the lysis of fibrin, thereby promoting clot formation.

  • Indications: Prevention and treatment of excessive bleeding caused by hyperfibrinolysis or surgical complications. They are also used to treat Hemophilia A or Type I von Willebrand's disease (specifically desmopressin).

  • Examples:

    • aprotinin (Artiss, Trasylol)

    • tranexamic acid (Cyklokapron)

    • desmopressin acetate (DDAVP)

  • Adverse Effects: Generally uncommon and mild. Rare reports of thrombotic events. Other effects include dysrhythmia, orthostatic hypotension, bradycardia, headache, dizziness, fatigue, hallucinations, convulsions, and GI distress.

Comprehensive Nursing Implications

  • General Assessment: Check patient history, medication history, allergies, contraindications, baseline vital signs, laboratory values, and history of abnormal bleeding conditions.

  • Heparin Administration:

    • Intravenous doses are usually double-checked with a second nurse.

    • Subcutaneous doses must be given in deep subcutaneous fat, not intramuscularly.

    • Rotate injection sites.

    • Do not administer within 5 cm5\,cm of the umbilicus, abdominal incisions, open wounds, scars, drainage tubes, stomas, or areas of bruising/oozing.

    • Do not aspirate the injection or massage the site, as this may cause hematoma formation.

    • Anticoagulant effects of IV heparin are immediate; monitor aPTT daily.

  • LMWH Administration: Given subcutaneously in the abdomen; rotate sites. Protamine sulphate is the antidote.

  • Warfarin Administration:

    • Often started while the patient is still on heparin until PT/INR reaches therapeutic levels (crossover or bridge therapy).

    • Full effect takes several days.

  • Thrombolytic Administration: Follow strict manufacturer guidelines for preparation. Monitor IV sites for bleeding, redness, or pain. Watch for internal bleeding signs: decreased blood pressure, restlessness, and increased pulse.

Patient Education and Dietary Interactions

  • Education Topics: Importance of regular lab testing, signs of abnormal bleeding, and measures to prevent bruising or tissue injury.

  • Safety: Patients should wear a medical alert bracelet.

  • Dietary Restrictions: Patients on warfarin must maintain a consistent intake or avoid foods very high in Vitamin K, such as tomatoes and dark leafy green vegetables.

  • Natural Health Products: Consult a physician before using herbals, as many increase bleeding risk:

    • Capsicum pepper

    • Garlic

    • Ginger

    • Ginkgo

    • St. John's wort

    • Feverfew

Questions and Discussion

  • Question: A patient is receiving an IV infusion of heparin and was started on warfarin therapy the night before. Which statement is most correct?

    • Response: The heparin provides anticoagulation until therapeutic levels of warfarin are reached.

  • Question: A patient is receiving an IV infusion of a thrombolytic drug for acute myocardial infarction. The nurse notices a slight amount of bleeding from a recent lab draw site in the antecubital area. What is the first action?

    • Response: Apply pressure to the site with a gauze pad.

  • Question: A 75-year-old man on warfarin and an antidysrhythmic falls and hits his head, resulting in a small scalp lump but no external bleeding. What is the main concern?

    • Response: He needs to be examined for possible internal bleeding relating to the fall.

  • Question: A 72-year-old woman takes a multivitamin with ginkgo and is recommended to start low-dose aspirin for TIAs. What is the concern?

    • Response: Increased risk of bleeding because of the ginkgo.

  • Case Study: Conversion from Heparin to Warfarin

    • Question 1: What are the considerations for converting IV heparin to oral warfarin?

    • Answer: Overlap therapy of IV heparin and warfarin for 33 to 55 days.

    • Question 2: Which lab result determines the next dose of warfarin during conversion?

    • Answer: PT/INR.

    • Question 3: What recommendation is part of dietary teaching for warfarin?

    • Answer: Limit intake of tomatoes.

    • Question 4: If the patient takes too much warfarin and is admitted with bleeding, which drug is anticipated?

    • Transcript Answer Provided: tenecteplase (TNKase). [Note: Standard clinical practice indicates Vitamin K for warfarin toxicity].